iADC：以STING 激动剂为payload，布局肿瘤免疫2.0。下一代ADC 平台"iADC"创新性地以ADC 形式通 过抗体介导的特异性识别，将STING 激动剂精准输送至肿瘤细胞，避免全身暴露，将冷肿瘤转化成热 肿瘤治疗PD-1 抗体无效的患者。平台首个临床候选药物HER2-STING iADC（JAB-BX467）前已确定 PCC，公司计划于2026H2 提交IND。此外，通过将专有STING 激动剂与不同的TAA 靶向抗体共轭，公 司正在开发一系列iADC 项目。iADC 平台经概念验证后，以STING 激动剂作为载荷的新型ADC 有望应 对ICI 疗法低反应率及传统ADC 毒性层面的双重挑战。 tADC：以KRAS 抑制剂为payload，开辟靶向治疗新范式。公司将高效KRASG12D 小分子抑制剂JAB- 22000 与抗体偶联，创新性构建KRAS G12D tADC平台。平台首个临床候选药物EGFR G12Di tADC （JAB-BX600）目前已确定PCC，公司计划于2026H2 提交IND。此外，研发管线中有多个未公开的 ADC候选药物正在积极推进中。tADC 平台经概念验证后，具备显 ...

Group 1 - The core viewpoint of the news highlights the performance and trends of the Hong Kong innovative drug sector, particularly focusing on the Hong Kong Stock Connect Innovative Drug ETF (159570), which has seen significant capital inflow and is leading in scale among similar funds [1][2] - The 44th JPMorgan Healthcare Conference showcased several Chinese innovative pharmaceutical companies, emphasizing trends in gene and cell therapy, as well as AI in medicine, indicating a shift from "assets being bought" to "global value" for Chinese innovations [1][2] - The innovative drug sector is expected to reach new highs due to various catalysts, including the significant valuation gap between China and the US, ongoing business development (BD) transactions, and low current allocation of pharmaceutical theme funds in the market [2] Group 2 - Major stocks within the Hong Kong Stock Connect Innovative Drug ETF mostly experienced declines, with notable drops exceeding 1% for companies like BeiGene, China Biologic Products, and others, while CSPC Pharmaceutical showed a slight increase [2][3] - Key innovative drugs presented at the JPMorgan Conference include BeiGene's CDK4 products and the first BCL2 inhibitor approved in China, which highlights the competitive landscape and advancements in treatment options for various cancers [5][6] - The collaboration between Rongchang Biopharmaceutical and AbbVie on the PD-1/VEGF dual antibody RC148 is a significant development, with potential milestone payments and royalties, showcasing the growing internationalization of Chinese innovative drugs [9][10]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [5] Core Insights - Domestic innovative drugs are expected to lead the tumor immunotherapy 2.0 era, with bispecific antibodies becoming a global focus and business development (BD) transaction volumes reaching new highs. The global value of Chinese innovative drugs is being rapidly uncovered [3][6] - A significant collaboration was established between Rongchang Biopharma and AbbVie, involving the PD-1/VEGF bispecific antibody (RC148), which includes a $650 million upfront payment and potential milestone payments of up to $4.95 billion, along with double-digit royalties on net sales outside Greater China. This partnership accelerates the internationalization of RC148 and highlights the potential of the tumor pipeline [6] - The report emphasizes the increasing interest from multinational pharmaceutical companies in domestic bispecific antibody drugs, indicating that these innovative drugs will be a key growth engine in the tumor immunotherapy 2.0 era [6] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry is positioned for growth, particularly in the area of innovative drugs and tumor immunotherapy [5] Investment Recommendations and Targets - Key investment targets include Rongchang Biopharma (688331), 3SBio (01530), 3SBio Guojian (688336), Innovent Biologics (01801), CanSino Biologics (09926), Kintor Pharmaceutical (06990), and Eucure Biopharma (09606), all of which are not rated yet [3] Recent Developments - The collaboration between Rongchang Biopharma and AbbVie is a pivotal event, marking a significant step in the global commercialization of innovative drugs [6]

Core Viewpoint - Kangfang Biopharma (09926) has seen a stock increase of over 3%, currently at 121.9 HKD, with a trading volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody, Cadonilimab, for a Phase III clinical trial [1] Group 1 - The FDA has approved the international multicenter Phase III clinical study (COMPASSION-37/AK104-311) for Cadonilimab in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - COMPASSION-37 is the second international multicenter registration clinical study for Cadonilimab, following a previous study for immune-resistant hepatocellular carcinoma that has already commenced in the U.S. [1] - The initiation of the COMPASSION-37 study marks a significant step forward in the global development of Cadonilimab and is a key initiative in Kangfang Biopharma's globalization strategy, reinforcing its international leadership in the field of tumor immunotherapy 2.0 [1]

Core Viewpoint - 康方生物's stock has increased by over 3%, currently trading at 121.9 HKD with a transaction volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody, 卡度尼利单抗, for a pivotal clinical trial [1] Group 1: Company Developments - 康方生物 announced the initiation of the COMPASSION-37/AK104-311 international multicenter phase III clinical study, which evaluates 卡度尼利单抗 in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - This study represents the second international multicenter registration clinical trial for 卡度尼利, following a previous study focused on immune-resistant hepatocellular carcinoma that has already commenced in the United States [1] - The launch of the COMPASSION-37 study is a significant step forward in the global development of 卡度尼利 and is a key initiative in 康方生物's globalization strategy, reinforcing its leading position in the field of tumor immunotherapy 2.0 [1]

Core Viewpoint - 康方生物's stock has increased by over 3%, currently trading at 121.9 HKD with a transaction volume of 271 million HKD, following the announcement of FDA approval for its innovative PD-1/CTLA-4 bispecific antibody,卡度尼利单抗, for a pivotal clinical trial [1] Group 1 - 康方生物 announced the FDA approval for the international multicenter phase III clinical study (COMPASSION-37/AK104-311) of 卡度尼利单抗 in combination with chemotherapy for HER2-negative, untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - The COMPASSION-37 study is the second international multicenter registration clinical study for 卡度尼利单抗, following a previous study for immune-resistant hepatocellular carcinoma [1] - The initiation of the COMPASSION-37 study marks a significant step forward in the global development of 卡度尼利单抗 and is a key initiative in 康方生物's globalization strategy, reinforcing its leading position in the tumor immunotherapy 2.0 field [1]

Core Viewpoint - The company, Weili Zhibo, has emerged as a standout player in the Hong Kong IPO wave for innovative drug companies, successfully raising nearly 1.4 billion HKD after its stock price doubled on the first day of trading, marking it as the "first TCE stock" [1] Group 1: Company Overview - Weili Zhibo is a tumor immunotherapy company based in Nanjing, Jiangsu, with 14 candidate drugs, 6 of which are in clinical trial stages [1] - The company aims to submit 5 new drug IND applications by 2026, focusing on expanding its key pipeline drug LBL-024 to treat 8-10 tumor indications, including non-small cell lung cancer and melanoma [1][2] Group 2: Drug Development Strategy - The founder emphasizes the importance of differentiation in the competitive tumor treatment field, aiming to develop unique drugs that address unmet patient needs [1][2] - LBL-024 targets PD-L1 and 4-1BB, attempting to conditionally activate 4-1BB to convert "cold tumors" into "hot tumors," thereby enhancing T-cell response [3][4] - The drug's clinical trial data shows a significantly lower incidence of liver toxicity compared to traditional 4-1BB agonists, with 175 patients enrolled in trials as of June this year [5] Group 3: Clinical Progress and Future Plans - The company has reported promising results for LBL-024 in treating small cell lung cancer, with an objective response rate of 86.5% and a disease control rate of 96.2% in a small sample [7] - Plans are in place to initiate Phase II clinical trials for LBL-024 in multiple indications, including non-small cell lung cancer and cholangiocarcinoma, while employing an efficient trial strategy to minimize costs [7][8] Group 4: Financial Strategy and Market Position - The company has successfully raised funds during favorable market conditions, increasing its fundraising target significantly to support ongoing research and development [10] - Collaborations and partnerships are seen as crucial for cash flow, with the company having previously partnered with BeiGene and currently seeking new collaborations to enhance the value of its drug pipelines [10][12] Group 5: Pipeline and Future Innovations - In addition to LBL-024, the company is developing LBL-034, a TCE targeting GPRC5D for treating relapsed/refractory multiple myeloma, which has shown a high objective response rate of 90% in clinical trials [11] - The company is focused on improving research efficiency and maintaining a stable development team to drive innovation in a competitive market [12]

Group 1 - Nanjing Weilizhibo Biotechnology Co., Ltd. officially listed on the Hong Kong Stock Exchange, becoming the third Nanjing company to go public this year, raising the total number of listed companies in Nanjing to 165 [1][2] - Weilizhibo focuses on the discovery, development, and commercialization of new therapies for tumors, autoimmune diseases, and other major diseases, with a pipeline of 12 products including monoclonal antibodies and antibody-drug conjugates [2][3] - The company has developed proprietary technology platforms such as LeadsBodyTM and X-bodyTM, which optimize the balance between efficacy and safety, aiming to improve patient quality of life [2][3] Group 2 - The company raised $189 million, which will be primarily used for clinical drug development, optimizing technology platforms, and increasing production capacity [3] - Weilizhibo has established a first-mover advantage in the solid tumor treatment market with a differentiated T-cell engager (TCE) product matrix covering hematological tumors, solid tumors, and autoimmune diseases [3] - Following Weilizhibo's listing, Nanjing's capital market is set to expand further with another company, Hansan (Nanjing) Technology Co., Ltd., expected to go public next month, increasing the total to 166 listed companies [4][5]

Group 1: Yimutian Inc. (一亩田) - Yimutian Inc. plans to go public on NASDAQ under the ticker "YMT" with an expected IPO date at the end of July 2023, aiming to raise up to $26 million by issuing 4.522 million American Depositary Shares (ADS) priced between $4.10 and $5.00 each [3][4] - Established in 2011, Yimutian has evolved from an information service platform to a comprehensive digital agriculture enterprise, serving over 56 million users and covering more than 340 cities and 2,800 counties in mainland China, capturing over 65% of the primary and secondary agricultural wholesale market [4] - The company has developed a new offline store model called "沃来采" to meet the needs of emerging buyers, leveraging its extensive buyer channels and market data to provide standardized and efficient agricultural brokerage services [4][5] Group 2: Weili Zhizhi Bio (维立志博) - Weili Zhizhi Bio officially listed on the Hong Kong Stock Exchange under the ticker "9887" on July 25, 2025, raising approximately HKD 1.29 billion by issuing 36,862,500 shares at an offer price of HKD 35.00 each [7][8] - The company attracted nine cornerstone investors, securing a total of USD 69 million (approximately HKD 541.6 million) in subscriptions, with notable contributions from firms like Tencent and various investment funds [8] - As a clinical-stage biotechnology company founded in 2012, Weili Zhizhi focuses on discovering and commercializing new therapies for cancer and autoimmune diseases, boasting a diverse product portfolio of 14 innovative candidates, including four core products that are leading in global clinical progress [9]